PPAR ligands reduce obesity-associated comorbidities by acting on fat storage capacity of WAT and fat burning in BAT and/or peripheral ... Peroxisome proliferator-activated receptor-α agonist, ...

Troglitazone-suppressed stomach cancer via activation of PPAR-gamma, and stomach cancer was suppressed by apoptosis mediated by PPAR-gamma ligands. After we confirmed the appearance of PPAR-gamma ...

PPAR-ligands are emerging as a new type of cancer therapy because they directly target errant cells and stop tumor growth, at least in animal models.

However, PPARs manifest dual functions, ... Additionally, the structural heterogeneity of PPAR ligands complicates the development of universally applicable pharmacophores.

PPARs exhibit a dualistic nature in cancer therapy, ... Additionally, the structural heterogeneity of PPAR ligands complicates the development of universally applicable pharmacophores.

Via Megan McArdle, Derek Lowe blogs today about an entire field of pharmaceutical research revolving around PPAR ligands that pretty much went nowhere and cost drug companies a bundle: Allow me to ...

Peroxisome proliferator-activated receptor (PPAR) agonists are used as adjunct therapy in the treatment of diabetes mellitus. Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, ...

The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of glucose and lipid metabolism. They are activated by natural ligands, such as fatty acids, and are also target ...

Peroxisome Proliferator-Activated Receptor Ligands Enhance Human B Cell Antibody Production and Differentiation. The Journal of Immunology , 2009; 183 (11): 6903 DOI: 10.4049/jimmunol.0900324 Cite ...

Background: Peroxisome proliferator-activated receptor-gamma (PPARγ) ligands have been identified as a potential source of therapy for human cancers. And, it is reported that PPAR-γ ligands could ...

PPARs exhibit a dualistic nature in cancer therapy, ... Additionally, the structural heterogeneity of PPAR ligands complicates the development of universally applicable pharmacophores.